Log In
Print
BCIQ
Print
Print this Print this
 

MKC1106-PP

  Manage Alerts
Collapse Summary General Information
Company MannKind Corp.
DescriptionPlasmid DNA encoding preferentially expressed antigen of melanoma (PRAME) and prostate-specific membrane antigen (PSMA) plus synthetic peptide analogs of PRAME and PSMA
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid malignancies
Regulatory Designation

Partner

Colby Pharmaceutical Co.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$140.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today